Track Cellebrite DI Ltd. Ordinary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cellebrite DI Ltd. Ordinary Shares CLBT · Stock Open Cellebrite DI Ltd. Ordinary Shares in new tab

11.53 USD
P/E
55.22
EPS
0.23
P/B
5.92
ROE
12.42
Beta
1.01
Target Price
15.36 USD
Cellebrite DI Ltd. Ordinary Shares logo

Cellebrite DI Ltd. Ordinary Shares

🧾 Earnings Recap – Q3 2026

Cellebrite shares fell 9.2% after earnings, despite Q3 results above company guidance. The transcript points to lingering concern about the outlook: management described the U.S. go-to-market response as improved after Q2 and said updated financial guidance would follow, but the supplied remarks do not include the revised outlook.

  • CEO said Q3 ARR, revenue and adjusted EBITDA finished above company guidance; international performance and a reaccelerating U.S. federal business drove top-line growth.
  • EMEA grew 22% and Asia-Pacific 31%. Two large U.S. federal customers each increased spending by more than 20% year over year.
  • Genesis ended its first full quarter with $2 million in ARR. Inseyets conversions rose from nearly 65% of the install base at Q2-end to 75% at Q3-end.
  • Advanced unlocks doubled customers versus Q2, with strong sequential ARR growth; defense and intelligence continued growing in the mid-20s.
  • Management said it plans to introduce an on-premise AI version of Genesis before year-end and expects to deliver updated mobile-forensics capabilities and next-generation hardware before year-end.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 10, 2027
P/E55.22
EPS0.23
Book Value2.15
Price to Book5.92
Debt/Equity4.32
% Insiders44.100%
Growth
Revenue Growth0.16%
Earnings Growth-0.68%
Estimates
Forward P/E19.44
Forward EPS0.65
Target Mean Price15.36

DCF valuation

Model fair value for Cellebrite DI Ltd. Ordinary Shares (CLBT)
Result
Sign in to run the valuation for CLBT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus None · mean target 15.36 USD (low 12.50, high 20.00) · as of 10 Nov 2026
Low 12.50
Mean 15.36
High 20.00
Price 11.53
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cellebrite DI Ltd. Ordinary Shares Logo Cellebrite DI Ltd. Ordinary Shares Analysis (CLBT)

Israel Information Technology Official Website Stock

Is Cellebrite DI Ltd. Ordinary Shares a good investment? Cellebrite DI Ltd. Ordinary Shares (CLBT) is currently trading at 11.53 USD. Market analysts have a consensus price target of 15.36 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 55.22. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Cellebrite DI Ltd. Ordinary Shares is expected to release its next earnings report on Feb. 10, 2027. The market consensus estimate for Forward EPS is 0.65.

Investor FAQ

Does Cellebrite DI Ltd. Ordinary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cellebrite DI Ltd. Ordinary Shares?

Cellebrite DI Ltd. Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 10, 2027. The company currently has a trailing EPS of 0.23.

Company Profile

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.

Exchange Ticker
NMS (United States) CLBT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion